digital-business-models-in-healthcare-book-matthias-puls.png

Interview

In conversation with
Jens Nörtershäuser

Jens Nörtershäuser is building Kranus Health, a physician-prescribed, insurer-reimbursed digital therapeutics company specializing in urology—delivering virtual care that goes beyond medication toward holistic, sustainable outcomes. Think modern “pharma-like” access (prescriptions, coverage) fused with software rigor and clinical evidence, including studies published in NEJM Evidence, now scaling from Germany into France. The intent is clear: redesign pathways so patients gain timely, stigma-free care while systems improve the cost–outcome equation.

Pre-order the book

Measure success in years of healthy life added per euro spent.

LESSONS FROM PRESCRIBED DIGITAL UROLOGY:
Evidence, Market Access, and Real-World Usability

Nörtershäuser’s playbook sits at the intersection of pharma economics and tech velocity: earn prescriber trust with rigorous trials, win reimbursement to reach scale, and design experiences that patients actually use. He argues leaders must plan on long horizons, over-index on market access and regulatory strategy, and ignore “that’s how reimbursement works” fatalism—test assumptions and prove value in real workflows. Friction points are cultural (safety-first pharma vs. speed-first tech) and structural (privacy and consent UX that deters use); the counter is explainable products, simpler consent, and outcomes that matter to payers and clinicians alike.

What we cover

How a physician-prescribed, insurer-reimbursed DTx model expands access in urology
Why clinical evidence and real-world workflow fit beat hype for prescriber trust and scale
What leadership habits—long-range planning, market-access fluency, disciplined hiring—sustain momentum
Where privacy, consent design, and culture clashes slow adoption—and how to resolve them
Which funding paths to pursue as you grow—European proof, early U.S. relationships, and stage-specific milestones

Jens Nörtershäuser is the CEO and co-founder of Kranus Health, a digital health company delivering prescription-based therapeutics that merge pharmaceutical science with software in the sector of urology. After many years at McKinsey & Company advising global pharma clients, he joined Palantir Technologies pre-IPO, being involved firsthand in the experience of changing the world through technology out of Silicon Valley. In 2020, he co-founded Kranus Health, has since raised more than €25 million in venture capital, and now holds full revenue and profitability responsibility and oversees the overall development of the company including international expansion.